IRIS
BORDI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.332
EU - Europa 1.108
AS - Asia 679
AF - Africa 18
SA - Sud America 2
OC - Oceania 1
Totale 3.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.322
CN - Cina 310
IT - Italia 289
SG - Singapore 284
SE - Svezia 278
IE - Irlanda 268
DE - Germania 61
FR - Francia 43
AT - Austria 39
FI - Finlandia 38
IN - India 23
TR - Turchia 22
CI - Costa d'Avorio 16
NL - Olanda 15
BE - Belgio 14
CZ - Repubblica Ceca 14
ID - Indonesia 13
CA - Canada 10
GB - Regno Unito 10
RU - Federazione Russa 7
LU - Lussemburgo 6
HK - Hong Kong 5
IR - Iran 5
LT - Lituania 5
AL - Albania 3
IL - Israele 3
JP - Giappone 3
UA - Ucraina 3
AZ - Azerbaigian 2
BG - Bulgaria 2
DK - Danimarca 2
MD - Moldavia 2
RO - Romania 2
TH - Thailandia 2
VN - Vietnam 2
AR - Argentina 1
AU - Australia 1
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
IS - Islanda 1
KZ - Kazakistan 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 3.140
Salva come PNG Salva come JPEG
Città #
Chandler 302
Dublin 265
Singapore 220
Santa Clara 158
Ashburn 95
Boardman 91
Shanghai 82
Parma 70
Beijing 67
New York 61
Ann Arbor 60
Princeton 46
Vienna 38
Marseille 30
Helsinki 28
Des Moines 25
Wilmington 25
Milan 23
Bologna 20
Nanjing 20
Bremen 17
Dearborn 17
Munich 17
Abidjan 16
Verona 15
Chicago 14
Izmir 14
Jakarta 13
Jinan 13
Seattle 13
West Jordan 12
Brno 11
Los Angeles 11
Rome 10
Changsha 9
Guangzhou 9
Redmond 9
Brussels 8
Istanbul 8
Trento 8
Kunming 7
Falls Church 6
Frankfurt am Main 6
Fremont 6
Louvain-la-Neuve 6
Nanchang 6
Shenyang 6
Bolzano 5
Dallas 5
Hebei 5
Pune 5
Reggio Emilia 5
Toronto 5
Verdellino 5
Ardea 4
Hefei 4
Kochi 4
Leipzig 4
Modena 4
Newark 4
Phoenix 4
San Giuliano Milanese 4
Tianjin 4
Wayne 4
Amsterdam 3
Borås 3
Brescia 3
Fairfield 3
Grafing 3
Hangzhou 3
Hong Kong 3
Houston 3
Jiaxing 3
Kolkata 3
Kyiv 3
Lonato 3
London 3
Norwalk 3
Nuremberg 3
Olomouc 3
Redwood City 3
San Mateo 3
Scandiano 3
Tehran 3
Tirana 3
Zhengzhou 3
Antwerp 2
Baggiovara 2
Baku 2
Bhubaneswar 2
Cambridge 2
Central 2
Chisinau 2
Créteil 2
Dong Ket 2
Edinburgh 2
Florence 2
Genoa 2
Luxembourg 2
Marino 2
Totale 2.182
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 123
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 104
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 84
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 82
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 81
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 79
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 76
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 75
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 74
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 73
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 72
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 71
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 70
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 68
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 68
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 68
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 67
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 66
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 64
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 61
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 60
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 59
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA 57
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 56
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 55
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin 54
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 54
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer 53
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 52
Narrative literature and cancer: improving the doctor-patient relationship 52
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 52
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 51
227P Sexual dimorphism in immune profile of early and advanced NSCLC 50
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 49
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 49
Crizotinib resensitization by compound mutation 47
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC 46
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 46
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 45
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 43
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 39
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 36
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 35
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 35
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study 34
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH 31
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 29
Enteral administration of tkis: Report of a response to ceritinib in an alk-positive nsclc patient and literature review 29
Emerging role of gefitinib in the treatmentof non-small-cell lung cancer (NSCLC) 29
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 28
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: Patient selection and perspectives 27
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 26
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 25
Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer 24
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 22
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 21
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: A case report 21
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 20
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: A case report 19
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 19
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors 18
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 17
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 17
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 15
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 14
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 13
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 13
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 12
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 10
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 10
Totale 3.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.347
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.347
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020113 0 0 0 0 0 0 16 18 22 36 17 4
2020/202187 2 0 4 9 12 10 7 9 20 5 4 5
2021/2022255 2 10 6 17 5 6 48 16 8 4 25 108
2022/20231.119 128 140 58 93 115 120 16 65 311 4 51 18
2023/2024632 30 29 20 22 52 133 67 42 42 44 44 107
2024/2025808 50 115 160 142 147 180 14 0 0 0 0 0
Totale 3.244